Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Published:2020-12 Issue:6 Volume:78 Page:783-785
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Pal Sumanta K.,Escudier Bernard J.,Atkins Michael B.,Hutson Thomas E.,Porta Camillo,Verzoni Elena,Needle Michael N.,Powers Daniel,McDermott David F.,Rini Brian I.

Funder

AVEO Oncology

Publisher

Elsevier BV

Subject

Urology

Reference8 articles.

1. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

2. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors;Shah;Eur J Cancer,2019

3. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study;Ornstein;Lancet Oncol,2019

4. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial;Motzer;Lancet Oncol,2014

5. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study;Rini;Lancet Oncol,2020

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma;New England Journal of Medicine;2024-08-22

2. Treatment Landscape of Renal Cell Carcinoma;Current Treatment Options in Oncology;2023-12

3. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs;Journal of Clinical Oncology;2023-11-10

4. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles;Frontiers in Immunology;2023-08-11

5. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial;The Oncologist;2023-06-14